Author argues IBRX is set for a short squeeze with 37% short interest and 8 days to cover, citing upcoming major announcements and Saudi FDA approval of ANKTIVA as catalysts.
IBRX — LONG Short interest is around 37% with 8 days to cover, and pressure will start to build around $3.70-$3.80, potentially causing a short squeeze. Dr. Pat Soon-Shiong announced major announcements this week, and the Saudi FDA granted approval to ANKTIVA plus a checkpoint inhibitor, the first approved chemotherapy-free immunotherapy that activates both natural killer cells and killer T cells. The author sees this as the catalyst needed, along with the metrics and volume.
Fintel reporting short interest around 37% with 8 days to cover this thing may actually blow. World renowned doctor Dr. Pat Soon-Shiong announced a few days ago that they have some major announcements this week, followed by Saudi FDA granting approval to their ANKTIVA + checkpoint inhibitor the first approved chemotherapy-free immunotherapy that activates both natural killer cells and killer T cells, heralding the era of immunotherapy 2.0.
This Reddit post, published January 15, 2026, features u/SolidReporter8229 discussing IBRX. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/SolidReporter8229 · Tickers: IBRX